Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3689700 | 0.99 | ROCK2 (0.34) | ROCK2ROCK1LCKPTK6AURKB | |
| SCHEMBL3696844 | 0.89 | PROKR1 (0.36) | ROCK2ROCK1LCKPTK6AURKB | |
| Hydrochloric Acid SCHEMBL3695994 | 0.88 | PROKR1 (0.36) | ROCK2ROCK1LCKPTK6AURKB | |
| SCHEMBL27791696 | 0.88 | AURKB (0.36) | ROCK2ROCK1LCKPTK6AURKB | |
| SCHEMBL13262075 | 0.86 | AURKB (0.35) | ROCK2ROCK1LCKPTK6AURKB | |
| SCHEMBL3691323 | 0.85 | SCN9A (0.38) | ROCK2ROCK1LCKPTK6AURKB | |
| SCHEMBL3694558 | 0.84 | ADORA2A (0.37) | ROCK2ROCK1LCKPTK6AURKB | |
| SCHEMBL3685886 | 0.83 | MARK3 (0.35) | ROCK2ROCK1LCKPTK6AURKB | |
| SCHEMBL3683970 | 0.82 | ROCK2 (0.51) | ROCK2SCN9APROKR1 | |
| SCHEMBL3696196 | 0.82 | ROCK2 (0.43) | ROCK2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| CN-101842098-A | Nitrogen-containing bicyclic chemical entities for the treatment of viral infections | GENELABS TECH INC | 2010-09-22 | — | — | CN | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | ROCK2 4811/4885ROCK1 4780/4885LCK 2497/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | ROCK2 4811/4885ROCK1 4780/4885LCK 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.